Observational Study of Lymphoma Patients by Genetic Subtype
Collects treatment and survival information from adults with diffuse large B-cell lymphoma by genetic subtype.
Plain-language title generated from the registry record
Registry title: Real-World Study of DLBCL With Different Genetic Subtypes
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT06026488
- Record updated
- 19 December 2024
- Original description
To collect and evaluate the data of real-world treatment regimen, efficacy, safety and survival information of DLBCL patients with different genetic suptypesRead full original descriptionShow less
A Real-World Study of Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Different Genetic Subtypes
To collect and evaluate the data of real-world treatment regimen, efficacy, safety and survival information of DLBCL patients with different genetic suptypes
Inclusion: Histologically-confirmed diffuse large B-cell lymphoma (DLBCL); Genetic subtype belonging to at least one of the seven subtypes by using next generation sequencing: MCD, BN2, N1, ST2, A53, EZB (MYC+, MYC-) and others; Fully comprehension and signature of the informed consent form (ICF) for participation.
Exclusion: Severe mental illness; Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period; Patients deemed unsuitable for inclusion by the investigator.